Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $416,000 | -43.2% | 25,674 | 0.0% | 0.00% | -42.9% |
| Q3 2021 | $733,000 | -15.6% | 25,674 | 0.0% | 0.01% | -12.5% |
| Q2 2021 | $868,000 | +11.9% | 25,674 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $776,000 | -23.8% | 25,674 | +24.7% | 0.01% | -20.0% |
| Q4 2020 | $1,019,000 | +29.0% | 20,584 | 0.0% | 0.01% | +11.1% |
| Q3 2020 | $790,000 | -11.1% | 20,584 | 0.0% | 0.01% | -18.2% |
| Q2 2020 | $889,000 | +48.2% | 20,584 | -10.5% | 0.01% | +37.5% |
| Q1 2020 | $600,000 | +30.7% | 22,992 | +56.4% | 0.01% | +60.0% |
| Q4 2019 | $459,000 | – | 14,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |